March 17, 2021
Today a review article discussing the goal of personalized medicine approaches in type 1 diabetes (T1D) was published in Diabetes. Authors Peter Linsley, PhD, Carla Greenbaum, MD, and Gerald Nepom, MD, PhD, the complex path to personalized medicine for T1D.
The goal of personalized medicine is to match the right drugs to the right patients at the right time. This approach has been most successful in diseases where there is a clear genetic linkage between a disease and a therapy. However, T1D is a genetically complex autoimmune disease.
Researchers have found that they can use autoantibodies as predictive biomarkers for disease risk and to monitor clinical trials. However, the biomarkers associated with disease progression are highly heterogeneous and complex.
Recent studies are using new biomarker-based principles to determine how to achieve personalized therapies for T1D. In addition, there is a focus on data-driven pathway-targeted approaches for combination therapies in which the therapeutic agents have complementary therapies.
For more information, read the full review article.
More Information
